By Len Zehr Athersys (NASDAQ:ATHX) expects to complete enrollment by the end of the summer in a Phase 2 clinical trial of its MultiStem cell therapy in about 140 moderate to moderately-severe ischemic stroke patients...
By Len Zehr “It is entirely the goal of Knight Therapeutics (TSX:GUD) to duplicate the success of Paladin Labs,” says president and CEO, Jonathan Ross Goodman, who turned Paladin into a premier distributor of specialty...
By Len Zehr As a co-founder, president and CEO of closely held viDA Therapeutics, a tissue repair company, Alistair Duncan has developed an affinity for doing biotech startups. From 1998 to 2008, he was president and...
By Len Zehr So says Vaughn Embro-Pantalony, president and CEO of Microbix Biosystems (TSX:MBX), referring to the company’s livestock semen sexing technology, LumiSort, and its manufacturing of infectious disease...
By Len Zehr Fresh from a US$52-million private placement, Aurinia Pharmaceuticals (TSX-V:AUP) hopes to treat its first lupus patient at the end of April in a Phase 2b clinical trial with its voclosporin...
By Len Zehr Upstart Gour Medical Animal Health, which recently agreed to acquire a portfolio of four products to be reformulated for pet care, is also negotiating for three or four additional products. “We are...
By Len Zehr “Our goal is to transform the way brain surgery is performed to advance better treatment options for patients for whom current therapies are deficient.” So says Kimble Jenkins, CEO of MRI Interventions...
By Len Zehr Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has added late-stage drug development to its operations with its acquisition from Perrigo plc (NYSE, TASE:PRGO) of neuropsychiatric drug candidate, ELND005...
By Len Zehr Closely held Alpha Cancer Technologies, which is going public in a reverse takeover of Bradmer Pharmaceuticals (TSX-V:BMR-H), plans to begin testing patients with ovarian cancer this year with its drug...
By Len Zehr Closely held Gamida Cell has shifted its focus to its second-generation stem cell product, NiCord, for the treatment of hematological malignancies and non-malignant hematological diseases in the wake of an...